QIAGEN, Astellas CDx Partnership
News Oct 30, 2014
QIAGEN N.V. announced a master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases. The scope of the agreement is not restricted to certain sample types, platforms, indications or biomarkers, thereby giving Astellas access to QIAGEN’s development capabilities for assays based on PCR, NGS and multi-modal testing technologies using liquid and tissue biopsies. Two initial projects in the collaboration focus on oncology and aim to pair QIAGEN diagnostics with Astellas compounds in early-stage clinical trials: ASP5878, a fibroblast growth factor receptor (FGFR) inhibitor, and ASP8273, an EGFR inhibitor. Financial terms were not disclosed.
“We are very pleased to partner with Astellas to help maximize the benefits of their innovative new drugs with companion diagnostics from our development and commercialization engine. QIAGEN shares Astellas’ commitment to contribute actively toward improving the health of patients by realizing the benefits of personalized healthcare,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “With the master agreement and the first two projects to be disclosed, QIAGEN is further expanding its leadership in personalized medicine – including in Japan, one of the world's largest markets for companion diagnostics. The master agreement provides Astellas and QIAGEN flexibility and a strong foundation to add further development projects across other therapeutic areas, across analytical techniques, and across a broad array of sampling options.”
New Portable Malaria Screening Instrument DevelopedNews
A new prototype for a portable instrument capable of early-stage malaria detection has been developed by a team of researchers at the USC Viterbi School of Engineering.READ MORE
Test Reliably Predicts Risk of Preterm BirthNews
Scientists at UC San Francisco have developed a test to predict a woman’s risk of preterm birth when she is between 15 and 20 weeks pregnant, which may enable doctors to treat them early and thereby prevent severe complications later in the pregnancy.READ MORE